Cerity Partners
EBS icon

Cerity Partners’s Emergent Biosolutions EBS Stock Holding History

Cerity Partners’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$281K Buy
33,586
+10,453
+45% +$87.5K ﹤0.01% 2841
2026
Q1 		$192K Buy
23,133
+4,718
+26% +$48.9K ﹤0.01% 2892
2025
Q4 		$228K Buy
18,415
+571
+3% +$6.12K ﹤0.01% 2564
2025
Q3 		$157K Buy
+17,844
New +$139K ﹤0.01% 2554

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Cerity Partners's EBS Position: Q2 2026 in Review

Cerity Partners increased its Emergent Biosolutions (EBS) stake by 45% in Q2 2026, buying an estimated $87.5K and bringing the position to 33,586 shares worth $281K. The position accounts for ﹤0.01% of the portfolio, ranked #2841.

Cerity Partners first reported a position in EBS in Q3 2025 and has held it in 4 quarters since. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Cerity Partners held 33,586 shares of Emergent Biosolutions worth $281K as of Q2 2026.
  • Cerity Partners bought 10,453 Emergent Biosolutions shares in Q2 2026, an estimated $87.5K.
  • Emergent Biosolutions made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2841 holding.
  • Cerity Partners first reported a position in Emergent Biosolutions in Q3 2025 and has held it in 4 quarters since.
  • 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.